to those stricken. It was as if the highlanders had done everything imaginable to accelerate the spread of the disease.
“If this were a strain with sustainable transmission from human to human, I can’t imagine how many people would have died, how many lives would have been lost,” said Dr. Surya Dharma, who was head of communicable disease control for North Sumatra.
If there was any encouraging news from North Sumatra, it was only this: the novel strain had not spread beyond the one family. In its current form, the virus was still tough to catch. But influenza viruses inexorably mutate. It had now, for the first time, demonstrated the capacity to jump not only from one person to another, but also onto a third.
Only nine years earlier, flu specialists had assumed that this strain couldn’t infect anyone at all. When it had, alarms sounded around the world.
CHAPTER TWO
A Visitation from Outer Space
K eiji Fukuda had been anticipating this call his entire career. It came in August 1997, when he was busy caring for patients at San Francisco’s Mount Zion Hospital, deep into a clinical rotation he would do a couple of weeks each year to keep his skills as a physician sharp. After he came off the wards, a hospital staffer mentioned that the CDC, where Fukuda worked most of the year as the country’s top influenza investigator, had been trying to reach him.
Fukuda suspected something was wrong. He quickly returned the call, which had come from a laboratory in the CDC’s influenza branch, and the lab director filled him in on some tests her scientists had just completed on a sample from Hong Kong. It looked as though someone had been infected by a new virus, a novel strain of flu called H5N1. The victim had died.
“It was a jolt,” Fukuda recounted. “It was an unusual call. But it was the call you are kind of always waiting for in the field of influenza.”
His mind instantly started to race. This was a strain that had never before infected humans, at least as far as scientists knew. That meant no one had immunity to the pathogen and everyone could be vulnerable. “How many other people have been infected?” Fukuda wondered to himself at the time, adrenaline pumping. “Are we missing anyone else? Right now, what’s going on?”
It took a few hours to arrange a larger conference call. The CDC
hooked in Fukuda along with Dr. Nancy Cox, the chief of the influenza branch, who had been tracked down while vacationing with her family at a horse ranch in Wyoming. Flu was their field, some would say their obsession, and they instantly understood what was at stake. “The idea of a pandemic coming on is one of the things you know is always possible,” Fukuda said. “Perhaps this is the start of that pandemic.”
Joining them on the call from Hong Kong was Dr. Margaret Chan, a Canadian-trained doctor who ran the city’s health department. She had never spoken with Fukuda before. Nor did she know much about pandemic flu. Over the next decade, she would become intensely familiar with both, gaining a perspective on influenza shared by few on Earth. But in 1997, it was all new. Chan peppered the CDC specialists with questions. “Is this a big threat or not?” she asked. They admitted they weren’t sure. They explained that the lab might have made a mistake. Even if the test result was accurate, it might reflect merely a single, isolated infection. But they cautioned her that the case could also be a harbinger of something larger. Chan was quick to appreciate the horrific implications. She told them she needed help. Hong Kong couldn’t get to the bottom of this alone. Before the call was over, Fukuda knew he was bound for Asia.
Fukuda finished his rotation in San Francisco, then headed home to pack. He and his wife and two young daughters lived in a suburb of Atlanta, where he had worked for the CDC since 1990. In 1996, he had become chief of epidemiology in the influenza branch.
Fukuda had been bred for the job.
“If this were a strain with sustainable transmission from human to human, I can’t imagine how many people would have died, how many lives would have been lost,” said Dr. Surya Dharma, who was head of communicable disease control for North Sumatra.
If there was any encouraging news from North Sumatra, it was only this: the novel strain had not spread beyond the one family. In its current form, the virus was still tough to catch. But influenza viruses inexorably mutate. It had now, for the first time, demonstrated the capacity to jump not only from one person to another, but also onto a third.
Only nine years earlier, flu specialists had assumed that this strain couldn’t infect anyone at all. When it had, alarms sounded around the world.
CHAPTER TWO
A Visitation from Outer Space
K eiji Fukuda had been anticipating this call his entire career. It came in August 1997, when he was busy caring for patients at San Francisco’s Mount Zion Hospital, deep into a clinical rotation he would do a couple of weeks each year to keep his skills as a physician sharp. After he came off the wards, a hospital staffer mentioned that the CDC, where Fukuda worked most of the year as the country’s top influenza investigator, had been trying to reach him.
Fukuda suspected something was wrong. He quickly returned the call, which had come from a laboratory in the CDC’s influenza branch, and the lab director filled him in on some tests her scientists had just completed on a sample from Hong Kong. It looked as though someone had been infected by a new virus, a novel strain of flu called H5N1. The victim had died.
“It was a jolt,” Fukuda recounted. “It was an unusual call. But it was the call you are kind of always waiting for in the field of influenza.”
His mind instantly started to race. This was a strain that had never before infected humans, at least as far as scientists knew. That meant no one had immunity to the pathogen and everyone could be vulnerable. “How many other people have been infected?” Fukuda wondered to himself at the time, adrenaline pumping. “Are we missing anyone else? Right now, what’s going on?”
It took a few hours to arrange a larger conference call. The CDC
hooked in Fukuda along with Dr. Nancy Cox, the chief of the influenza branch, who had been tracked down while vacationing with her family at a horse ranch in Wyoming. Flu was their field, some would say their obsession, and they instantly understood what was at stake. “The idea of a pandemic coming on is one of the things you know is always possible,” Fukuda said. “Perhaps this is the start of that pandemic.”
Joining them on the call from Hong Kong was Dr. Margaret Chan, a Canadian-trained doctor who ran the city’s health department. She had never spoken with Fukuda before. Nor did she know much about pandemic flu. Over the next decade, she would become intensely familiar with both, gaining a perspective on influenza shared by few on Earth. But in 1997, it was all new. Chan peppered the CDC specialists with questions. “Is this a big threat or not?” she asked. They admitted they weren’t sure. They explained that the lab might have made a mistake. Even if the test result was accurate, it might reflect merely a single, isolated infection. But they cautioned her that the case could also be a harbinger of something larger. Chan was quick to appreciate the horrific implications. She told them she needed help. Hong Kong couldn’t get to the bottom of this alone. Before the call was over, Fukuda knew he was bound for Asia.
Fukuda finished his rotation in San Francisco, then headed home to pack. He and his wife and two young daughters lived in a suburb of Atlanta, where he had worked for the CDC since 1990. In 1996, he had become chief of epidemiology in the influenza branch.
Fukuda had been bred for the job.
Similar Books
